최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Biomolecules & therapeutics, v.21 no.3, 2013년, pp.190 - 195
Kwon, Yeo-Jung (College of Pharmacy, Chung-Ang University) , Jung, Jin-Joo (College of Pharmacy, Chung-Ang University) , Park, Na-Hee (College of Pharmacy, Chung-Ang University) , Ye, Dong-Jin (College of Pharmacy, Chung-Ang University) , Kim, Donghak (Department of Biological Sciences, Konkuk University) , Moon, Aree (College of Pharmacy, Duksung Women's University) , Chun, Young-Jin (College of Pharmacy, Chung-Ang University)
Cisplatin is a member of platinum-containing anti-cancer drugs that causes cross-linking of DNA and ultimately cancer cell apoptosis. The therapeutic function of cisplatin on various types of cancers has been widely reported but the side effects have been discovered together and nephrotoxicity has b...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
1 Damia G. Filiberti L. Vikhanskaya F. Carrassa L. Taya Y. D'Incalci M. Broggini M. Cisplatinum and taxol induce different patterns of p53 phosphorylation Neoplasia (2001) 3 10 16 10.1038/sj.neo.7900122 11326311
2 Devarajan P. Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther. (2007) 5 463 470 18449360
3 Donzelli E. Carfi M. Miloso M. Strada A. Galbiati S. Bayssas M. Griffon-Etienne G. Cavaletti G. Petruccioli M. G. Tredici G. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J. Neurooncol. (2004) 67 65 73 10.1023/B:NEON.0000021787.70029.ce 15072449
4 Dreier R. Schmid K. W. Gerke V. Riehemann K. Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem. Cell Biol. (1998) 110 137 148 10.1007/s004180050275 9720986
5 Ea H. K. Monceau V. Camors E. Cohen-Solal M. Charlemagne D. Liote F. Annexin 5 overexpression increased articular chondrocyte apoptosis induced by basic calcium phosphate crystals. Ann. Rheum. Dis. (2008) 67 1617 1625 10.1136/ard.2008.087718 18218665
6 Fernandez J. Gharahdaghi F. Mische S. M. Routine identification of proteins from sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels or polyvinyl difluoride membranes using matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS). Electrophoresis (1998) 19 1036 1045 10.1002/elps.1150190619 9638950
7 Franke R. M. Kosloske A. M. Lancaster C. S. Filipski K. K. Hu C. Zolk O. Mathijssen R. H. Sparreboom A. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary Nacetyl- beta-D-glucosaminidase Clin. Cancer. Res. (2010) 16 4198 4206 10.1158/1078-0432.CCR-10-0949 20601443
8 Hanigan M. H. Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther. (2003) 1 47 61 18185852
9 Harmers F. P. Gispen W. H. Neijt J. P. Neurotoxic sideeffects of cisplatin. Eur. J. Cancer (1991) 27 372 376 10.1016/0277-5379(91)90549-S 1827334
10 Kenis H. Hofstra L. Reutelingsperger C. P. Annexin A5: shifting from a diagnostic towards a therapeutic realm. Cell. Mol. Life Sci. (2007) 64 2859 2862 10.1007/s00018-007-7297-2 17876516
11 Kenis H. van Genderen H. Bennaghmouch A. Rinia H. A. Frederik P. Narula J. Hofstra L. Reutelingsperger C. P. Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry J. Biol. Chem. (2004) 279 52623 52629 10.1074/jbc.M409009200 15381697
12 Laurell G. Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope (1990) 100 724 734 10.1288/00005537-199007000-00008 2362532
13 Lokich J. Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol. (1998) 9 13 21 10.1023/A:1008215213739 9541678
14 Markoff A. Gerke V. Expression and functions of annexins in the kidney. Am. J. Physiol. (2005) 289 F949 956
15 Matsuda R. Kaneko N. Horikawa Y. Chiwaki F. Shinozaki M. Abe S. Yumura W. Nihei H. Ieiri T. Measurement of urinary annexin V by ELISA and its signifi cance as a new urinarymarker of kidney disease. Clin. Chim. Acta (2000) 298 29 43 10.1016/S0009-8981(00)00218-7 10876002
16 Moss S. E. Morgan R. O. The annexins. Genome Biol. (2004) 5 219 10.1186/gb-2004-5-4-219 15059252
17 Pepinsky R. B. Tizard R. Mattaliano R. J. Sinclair L. K. Miller G. T. Browning J. L. Chow E. P. Burne C. Huang K. S. Pratt D. Wachter L. Hession C. Frey A. Z. Wallner B. P. Five distinct calcium and phospholipid binding proteins share homology with lipocortin I. J. Biol. Chem. (1988) 263 10799 10811 2968983
18 Prestayko A. W. D'Aoust J. C. Issell B. F. Crooke S. T. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat. Rev. (1979) 6 17 39 10.1016/S0305-7372(79)80057-2 378370
19 Quasthoff S. Hartung H. P. Chemotherapy-induced peripheral neuropathy. J. Neurol. (2002) 249 9 17 10.1007/PL00007853 11954874
20 Raynal P. Pollard H. B. Annexins: the problem of assessing the biological role for a gene family of multifunctional calciumand phospholipid-binding proteins. Biochim. Biophys. Acta (1994) 1197 63 93 10.1016/0304-4157(94)90019-1 8155692
21 Reviakine I. Bergsma-Schutter W. Mazeres-Dubut C. Govorukhina N. Brisson A. Surface topography of the p3 and p6 annexin V crystal forms determined by atomic force microscopy. J. Struct. Biol. (2000) 131 234 239 10.1006/jsbi.2000.4286 11052896
22 Sherman S. E. Lippard S. J. Structural aspects of platinum anticancer drug-interactions with DNA. Chem. Rev. (1987) 87 1153 1181 10.1021/cr00081a013
23 Siddik Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene (2003) 22 7265 7279 10.1038/sj.onc.1206933 14576837
24 Treskes M. van der Vijgh W. J. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother. Pharmacol. (1993) 33 93 106 10.1007/BF00685326 8261581
25 Ungethum L. Kenis H. Nicolaes G. A. Autin L. Stoilova-McPhie S. Reutelingsperger C. P. Engineered annexin A5 variants have impaired cell entry for molecular imaging of apoptosis using pretargeting strategies. J. Biol. Chem. (2011) 286 1903 1910 10.1074/jbc.M110.163527 21078669
26 van den Eijnde S. M. Luijsterburg A. J. Boshart L. De Zeeuw C. I. van Dierendonck J. H. Reutelingsperger C. P. Vermeij-Keers C. In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure. Cytometry (1997) 29 313 320 10.1002/(SICI)1097-0320(19971201)29:4 3.0.CO;2-A 9415414
27 Vermes I. Haanen C. Steffens-Nakken H. Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods (1995) 184 39 51 10.1016/0022-1759(95)00072-I 7622868
28 Wang E. J. Snyder R. D. Fielden M. R. Smith R. J. Gu Y. Z. Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology (2008) 246 91 100 10.1016/j.tox.2007.12.031 18289764
29 Wang X. Martindale J. L. Holbrook N. J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. (2000) 275 39435 39443 10.1074/jbc.M004583200 10993883
30 Yamashita T. Nagano K. Kanasaki S. Maeda Y. Furuya T. Inoue M. Nabeshi H. Yoshikawa T. Yoshioka Y. Itoh N. Abe Y. Kamada H. Tsutsumi Y. Tsunoda S. Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochem. Biophys. Res. Commun. (2012) 421 140 144 10.1016/j.bbrc.2012.03.144 22497892
31 Yao X. Panichpisal K. Kurtzman N. Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. (2007) 334 115 124 10.1097/MAJ.0b013e31812dfe1e 17700201
※ AI-Helper는 부적절한 답변을 할 수 있습니다.